| abstract |
The present invention relates to antisense LNA oligonucleotides (oligomers) complementary to TLR2 pre-mRNA exon sequences, which are capable of inhibiting the expression of TLR2 protein. Inhibition of TLR2 expression is beneficial for a range of medical disorders including of lupus erythematosus, such as systemic lupus erythematosus (SLE), rheumatoid arthritis, asthma, psoriasis, renal ischemia/reperfusion injury, sepsis, lung disease, atherosclerosis, hypertension, myocardial infarction, stroke, Alzheimer's disease and cerebrovascular injury. |